Esbriet Can Prolong Pulmonary Fibrosis Patients’ Lives, Review of Several Studies Reports
Esbriet (pirfenidone) can prolong idiopathic pulmonary fibrosis (IPF) patients’ survival, according to a review of clinical trials covering the anti-inflammatory and anti-fibrotic agent. Researchers also said that Esbriet is safe, but does not help every IPF patient. The study, “Role of pirfenidone in the management of pulmonary fibrosis,”…